By Valerie Villegas, PA-C · Artifex Medical Aesthetics · Alexandria, Virginia
Medically reviewed by Valerie Villegas, PA-C
Last medically reviewed: September 2026
Patients often arrive with a product already in mind.
Sometimes it is the one they have used before. Sometimes it is the one a friend recommended. Increasingly, it is the one they saw advertised online.
The question is usually the same:
Is one better than Botox?
At Artifex, I offer four botulinum toxin type A products for aesthetic treatment: Botox® Cosmetic, Dysport®, Jeuveau®, and Daxxify®. They share a mechanism of action, but they are not interchangeable. They differ in formulation, dosing units, FDA-approved cosmetic indications, and the clinical evidence available for each product.1,2,3,4
Those differences matter.
But they are only part of the treatment decision.
Botox Cosmetic, Dysport, Jeuveau, and Daxxify are prescription botulinum toxin type A products. They work by reducing acetylcholine release at the neuromuscular junction, which temporarily decreases activity in the muscles that are treated.1,2,3,4
In aesthetic treatment, that can soften dynamic lines—lines that become more noticeable with expressions such as frowning, squinting, or raising the eyebrows.
All four have FDA approval for the temporary improvement of moderate-to-severe glabellar lines, commonly called frown lines or “11s,” in adults, although the labeled populations are not identical. Dysport’s U.S. cosmetic indication specifically applies to adults younger than 65 years.1,2,3,4
Their effects are temporary.
They are not, however, simply the same medication sold under four different names. Each product has its own formulation, potency assay, prescribing information, recommended dose, and dosing units.
Those units are not interchangeable between products.1,2,3,4
That distinction becomes especially important when patients try to compare doses or prices.
| Product | FDA-approved cosmetic indications in the U.S. | A useful distinction |
|---|---|---|
| Botox Cosmetic | Glabellar lines, lateral canthal lines, forehead lines, and platysma bands | Broadest current FDA aesthetic labeling of these four products1 |
| Dysport | Glabellar lines in adults younger than 65 | Product-specific dosing scale; evidence supports relatively early onset in many patients2,8 |
| Jeuveau | Glabellar lines | Studied directly against Botox in a randomized noninferiority trial3,5 |
| Daxxify | Glabellar lines | Peptide-containing formulation and approximately 24-week median duration in pivotal glabellar-line studies4,6 |
This table is not a ranking.
The products were not all studied against one another using identical populations, doses, endpoints, or follow-up schedules. Even the word duration can mean different things depending on what a study measured.
That is one reason I would be cautious with any advertisement that reduces a neuromodulator to a single number.
Botox Cosmetic has been used for cosmetic treatment in the United States for more than two decades. Its current FDA labeling includes glabellar lines, lateral canthal lines—commonly called crow’s feet—forehead lines, and platysma bands of the neck.1
For glabellar lines, its prescribing information describes a duration of effect of approximately three to four months.1
That history is useful clinically.
It does not mean Botox must be the best choice for every patient.
If someone has previously had Botox and liked the result, I want to understand that experience before recommending a change. What worked? What did not? Did the result last as long as expected? Was there enough movement? Too little?
A newer product is not automatically a better product, and familiarity is not a reason to dismiss a newer option either.
The treatment should have a reason behind it.
One difference becomes obvious as soon as patients compare treatment quotes: Dysport uses its own product-specific unit scale.
Its prescribing information is explicit that Dysport units cannot be compared with or converted into units of another botulinum toxin product.2
That means seeing a larger number of Dysport units does not mean someone is receiving a proportionally larger or stronger treatment.
It is simply a different measurement system.
Dysport is also frequently associated with relatively early onset. A systematic review of the aesthetic literature found that onset was most often reported within two to three days, although study methods varied and some patients responded earlier or later.8 The same review found that duration varied substantially among studies, with four months being the most commonly reported duration.8
That evidence is useful, but it does not prove that Dysport will work faster or last longer than another product for every patient.
I would also be cautious with descriptions such as “Dysport spreads more” or “Dysport gives a softer look.” Those phrases are common in aesthetic conversations, but they are too imprecise to serve as a treatment plan by themselves.
Product characteristics matter.
So do dose, dilution, anatomy, placement, and injection technique.
Jeuveau received U.S. approval for moderate-to-severe glabellar lines in adults in 2019.3
What makes its evidence particularly interesting is that its clinical development program included a randomized, double-blind trial comparing Jeuveau directly with Botox for glabellar lines.
The study enrolled 540 adults. Participants received 20 units of Jeuveau, 20 units of Botox, or placebo. At day 30, Jeuveau met the study’s prespecified noninferiority criterion compared with Botox for the primary outcome.5
That word deserves explanation.
Noninferiority does not mean the two products were proven identical.
It means the study was designed to determine whether Jeuveau’s performance was not worse than Botox by more than a predefined statistical margin for the outcome being studied.
The trial supports Jeuveau as an evidence-based alternative for glabellar-line treatment. It does not establish that every patient will experience identical onset, duration, movement, or satisfaction with the two products.
That is a much more useful way to understand the evidence than simply calling Jeuveau “the new Botox.”
Daxxify is the most recently approved of these four products.
Its formulation differs from the others.
The current prescribing information lists a proprietary 35-amino-acid peptide excipient called RTP004. Unlike the current ingredient lists for Botox Cosmetic, Dysport, and Jeuveau, Daxxify’s listed formulation does not include human serum albumin.1,2,3,4
Its most discussed distinction, however, is duration.
In the two pivotal randomized Phase III studies known as SAKURA 1 and SAKURA 2, 40 units of daxibotulinumtoxinA were compared with placebo for moderate-to-severe glabellar lines. Participants maintained none-or-mild glabellar-line severity for a median of approximately 24 weeks according to the specified composite study assessments.6
That is where the familiar “about six months” description comes from.
But the wording matters.
It does not mean that every patient will have an unchanged result for exactly six months.
It does not mean the effect suddenly disappears at six months.
And it does not establish that the same duration should be expected when the product is used in a different treatment area.
The pivotal trials also compared Daxxify with placebo, not simultaneously with Botox, Dysport, and Jeuveau.4,6
For a patient who places a high value on potentially increasing the time between treatments, those duration data can be meaningful.
Longer-lasting, however, is not automatically synonymous with better.
Duration is useful when it matches what the patient wants.
FDA approval applies to a particular product, indication, patient population, dose, and method of use evaluated through the regulatory process.
Botox Cosmetic currently has FDA approval for several aesthetic treatment areas. Dysport, Jeuveau, and Daxxify have more limited U.S. cosmetic labeling.1,2,3,4
Clinicians may also use an FDA-approved medication in a way that does not appear in its approved labeling. This is known as off-label use.
The FDA explains that, once a medication is approved, health-care providers generally may prescribe it for an unapproved use when they judge that use to be medically appropriate for a particular patient. The FDA has not, however, determined the drug to be safe and effective for that specific unapproved use.7
Off-label prescribing is not unusual in medicine.
But the distinction should be clear.
If I am recommending treatment outside a product’s FDA-approved cosmetic indication, that is something I want the patient to understand—not something hidden in fine print.
One of the easiest mistakes to make when comparing neuromodulators is to compare the advertised price per unit.
The problem is that the unit itself is product-specific.
The FDA-approved prescribing information for these products states that their potency units are not interchangeable with those of other botulinum toxin preparations.1,2,3,4
So:
20 units of one product should not be assumed to equal 20 units of another.
A more useful comparison is the entire treatment plan:
At Artifex, those details are discussed before treatment.
I do not begin with the vial.
I begin by looking at the patient.
What movement is creating the concern?
What does the face look like at rest and in motion?
What does the patient want to change?
Just as importantly, what do they not want to change?
Have they been treated before? What product was used? What did they like about the result? What did they dislike? How long did they feel it lasted? Did anything feel heavy, uneven, or too restricted?
Then there are practical preferences.
Some patients strongly value preserving movement. Some want to maximize the interval between visits. Some are comfortable with what they have used for years. Others are coming in precisely because they want to reconsider it.
Those preferences belong in the treatment plan.
A previous response is useful information, too. If someone tells me that a treatment wore off unusually quickly, caused heaviness, produced asymmetry, or simply never looked the way they hoped, changing brands might be reasonable.
But changing the vial does not automatically fix the reason it happened.
First, we need to understand what happened.
My goal is not to identify a universally “best” neuromodulator. It is to choose an appropriate product, dose, and injection pattern for the person sitting in front of me.
The product matters.
So do anatomy, dose, placement, treatment pattern, and clinical judgment.
I would resist trying to turn that relationship into a percentage. There is no defensible formula saying the product is 30% of the result and the injector is 70%.
What we can say is that choosing a brand does not replace an individualized assessment.
Even the Botox Cosmetic prescribing information notes that safe and effective use depends on factors including selection of the correct dose, administration technique, and an understanding of the relevant neuromuscular and structural anatomy.1
Two people receiving the same product do not necessarily need the same treatment pattern.
Their facial anatomy can differ.
Their muscle activity can differ.
Their treatment history can differ.
And their goals can be completely different.
That is why I do not think an aesthetic consultation should feel like choosing a brand from a menu.
A different neuromodulator can be considered at a subsequent treatment.
What matters is that your clinician knows what you previously received, when you received it, what areas were treated, and—when available—how much was used.
This matters because the units cannot simply be converted from one product to another, and prescribing information for these products includes precautions about cumulative exposure and treatment with other botulinum toxin products.1,2,3,4
If you were treated elsewhere, bring whatever information you have.
More history is better than guessing.
Botulinum toxin treatment is not instantaneous.
Changes develop over the days following treatment, and the first visible change is not necessarily the final result.
For Botox Cosmetic, the prescribing information describes initial chemical denervation beginning within one to two days and increasing during the first week.1 Dysport studies have frequently reported patient-noticed onset within approximately two to three days.8
Those are population-level observations, not a countdown clock for an individual patient.
The appropriate time to assess a treatment depends on the product, treatment area, and what is being evaluated.
There is no single product that can accurately be described as the safest choice for every patient.
All four products carry an FDA boxed warning concerning the potential for botulinum toxin effects to spread beyond the injection site.1,2,3,4 Their specific prescribing information, ingredients, contraindications, and adverse-event data are not identical.
One example of a product-specific difference is Dysport: its prescribing information lists known hypersensitivity to cow’s-milk protein as a contraindication and notes that the product may contain trace amounts of cow’s-milk protein.2
Potential adverse effects following aesthetic botulinum toxin treatment vary by product and treatment area. They can include injection-site reactions, headache, and unwanted weakness of nearby muscles, which can cause effects such as temporary eyelid or eyebrow drooping.1,2,3,4
Rarely, effects consistent with botulinum toxin can occur beyond the injection site. The boxed warnings describe potentially serious symptoms including difficulty swallowing, speaking, or breathing. Those symptoms require immediate medical attention.1,2,3,4
This is one reason your medical history, medications, previous botulinum toxin treatments, and other relevant health information should be reviewed before treatment.
That part of the appointment is not a formality.
Yes.
The four products are not interchangeable.
They differ in formulation, dosing, FDA-approved indications, and the clinical evidence available for them.
But choosing between them is not the same as choosing among four versions of the same consumer product.
The better question is:
Why is this product being recommended for me?
A good consultation should give you a clear answer.
At Artifex, we assess your anatomy and movement, talk about what you want treatment to accomplish, review relevant treatment history, and then decide whether a neuromodulator is appropriate—and, if so, which treatment approach makes sense.
The goal is not to sell you on a brand.
It is to develop a treatment plan you understand.
To discuss whether neuromodulator treatment is appropriate for you, book a consultation at Artifex Medical Aesthetics in Alexandria, Virginia. Consultations are $100 and are applied toward your first treatment.
This article is intended for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment. Treatment recommendations, response, onset, and duration vary among patients. Botox® Cosmetic, Dysport®, Jeuveau®, and Daxxify® are registered trademarks of their respective owners.
Offers valid through October 3, 2026. Leave your details and we'll reach out to get you scheduled.
, thank you. We'll be in touch soon to get you scheduled.
Want to lock in a time now? Book online.